Table 2.
Treatment-related AEs during MOVIE phase I
| Preferred term | Dose level 1 (N = 4) |
Dose level 2 (N = 10) |
Overall (N = 14) |
||||
|---|---|---|---|---|---|---|---|
| Grade 2 | Grade 2 | Grade 3 | Grade 4 | Grade 2 | Grade 3 | Grade 4 | |
| Anemia | 3 (30.0%) | 3 (21.4%) | |||||
| Asthenia | 8 (80.0%) | 3 (30.0%) | 8 (57.1%) | 3 (21.4%) | |||
| ALP increase | 3 (30.0%) | 3 (21.4%) | |||||
| Colitis | 1 (10.0%) | 1 (10.0%) | 1 (7.1%) | 1 (7.1%) | |||
| Constipation | 1 (25.0%) | 1 (7.1%) | |||||
| Decreased appetite | 1 (10.0%) | 1 (7.1%) | |||||
| Dermatitis exfoliative | 1 (10.0%) | 1 (7.1%) | |||||
| Diarrhea | 1 (10.0%) | 1 (7.1%) | |||||
| Dry skin | 2 (20.0%) | 2 (14.3%) | |||||
| GGT increase | 3 (30.0%) | 3 (21.4%) | |||||
| Hyperthyroidism | 3 (30.0%) | 3 (21.4%) | |||||
| Hypothyroidism | 1 (25.0%) | 1 (1.7%) | |||||
| Lymphocyte count increase | 1 (10.0%) | 1 (7.1%) | |||||
| Musculoskeletal pain | 1 (10.0%) | 1 (7.1%) | |||||
| Nausea | 2 (20.0%) | 2 (14.3%) | |||||
| Neutropenia | 1 (10.0%) | 1 (7.1%) | |||||
| Pruritus | 2 (20.0%) | 2 (14%) | |||||
| Rash maculopapular | 1 (10.0%) | 1 (7.1%) | |||||
AE, adverse event; ALP, alkaline phosphatase; GGT, γ-glutamyltransferase.